This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ge, Y. Articles by Taub, J. W. Search for Related Content PubMed PubMed Citation Articles by Ge, Y. Articles by Taub, J. W.

The Role of Cytidine Deaminase and GATA1 Mutations in the Increased Cytosine Arabinoside Sensitivity of Down Syndrome Myeloblasts and Leukemia Cell Lines

¹ Experimental and Clinical Therapeutics Program, Barbara Ann Karmanos Cancer Institute,
² Division of Pediatric Hematology/Oncology, Children’s Hospital of Michigan, and the
³ Departments of Pharmacology and
⁴ Pediatrics, Wayne State University School of Medicine, Detroit, Michigan

Myeloblasts from Down syndrome (DS) children with acute myeloid leukemia (AML) are significantly more sensitive in vitro to 1-ß-D-arabinofuranosylcytosine (ara-C) and generate higher 1-ß-D-arabinofuranosylcytosine 5'-triphosphate (ara-CTP) than non-DS AML myeloblasts. Semiquantitative reverse transcription-PCR analyses demonstrated that transcripts for cytidine deaminase (CDA) were 2.7-fold lower in DS than for non-DS myeloblasts. In contrast, transcripts of cystathionine-ß-synthase and deoxycytidine kinase were a median 12.5- and 2.6-fold higher in DS compared with non-DS myeloblasts. The ratio of deoxycytidine kinase/CDA transcripts significantly correlated with ara-C sensitivities and ara-CTP generation. In clinically relevant AML cell line models, high cystathionine-ß-synthase transcripts in DS CMK cells were accompanied by 10-fold greater ara-C sensitivity and 2.4-fold higher levels of ara-CTP compared with non-DS CMS cells. Overexpression of CDA in non-DS THP-1 cells was associated with a 100-fold decreased ara-C sensitivity and 40-fold decreased ara-CTP generation. THP-1 cells secreted CDA into the incubation media and converted extracellular ara-C completely to 1-ß-D-arabinofuranosyluracil within 30 min. Rapid amplification of 5'-cDNA ends (5'-RACE) and reverse transcription-PCR assays identified short- (sf) and long-form (lf) CDA transcripts in THP-1 cells with different 5' untranslated regions and translational start sites; however, only the latter resulted in the active CDA. Although 5' flanking sequences for both CDA transcripts exhibited promoter activity in reporter gene assays, activity for the CDAlf was low. The presence of several GATA1 binding sites in the CDAsf promoter and the uniform detection of GATA1 mutations in DS megakaryocytic leukemia suggested the potential role of GATA1 in regulating CDA transcription and the CDAsf promoter acting as an enhancer. Transfection of GATA1 into Drosophila Mel-2 cells stimulated the CDAlf promoter in a dose-dependent fashion. Additional identification of the mechanisms of differential expression of genes encoding enzymes involved in ara-C metabolism between DS and non-DS myeloblasts may lead to improvements in AML therapy.

This article has been cited by other articles:

				M. Han, C. T. Liew, H. W. Zhang, S. Chao, R. Zheng, K. T. Yip, Z.-Y. Song, H. M. Li, X. P. Geng, L. X. Zhu, et al. Novel Blood-Based, Five-Gene Biomarker Set for the Detection of Colorectal Cancer Clin. Cancer Res., January 15, 2008; 14(2): 455 - 460. [Abstract] [Full Text] [PDF]

				K. Kudo, S. Kojima, K. Tabuchi, H. Yabe, A. Tawa, M. Imaizumi, R. Hanada, K. Hamamoto, R. Kobayashi, A. Morimoto, et al. Prospective Study of a Pirarubicin, Intermediate-Dose Cytarabine, and Etoposide Regimen in Children With Down Syndrome and Acute Myeloid Leukemia: The Japanese Childhood AML Cooperative Study Group J. Clin. Oncol., December 1, 2007; 25(34): 5442 - 5447. [Abstract] [Full Text] [PDF]

				X. Ma, M. J. Renda, L. Wang, E.-c. Cheng, C. Niu, S. W. Morris, A. S. Chi, and D. S. Krause Rbm15 Modulates Notch-Induced Transcriptional Activation and Affects Myeloid Differentiation Mol. Cell. Biol., April 15, 2007; 27(8): 3056 - 3064. [Abstract] [Full Text] [PDF]

				Y. Ge, A. A. Dombkowski, K. M. LaFiura, D. Tatman, R. S. Yedidi, M. L. Stout, S. A. Buck, G. Massey, D. L. Becton, H. J. Weinstein, et al. Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia Blood, February 15, 2006; 107(4): 1570 - 1581. [Abstract] [Full Text] [PDF]

				M. Ogawa, H. Hori, T. Ohta, K. Onozato, M. Miyahara, and Y. Komada Sensitivity to Gemcitabine and Its Metabolizing Enzymes in Neuroblastoma Clin. Cancer Res., May 1, 2005; 11(9): 3485 - 3493. [Abstract] [Full Text] [PDF]

				Y. Ge, M. L. Stout, D. A. Tatman, T. L. Jensen, S. Buck, R. L. Thomas, Y. Ravindranath, L. H. Matherly, and J. W. Taub GATA1, Cytidine Deaminase, and the High Cure Rate of Down Syndrome Children With Acute Megakaryocytic Leukemia J Natl Cancer Inst, February 2, 2005; 97(3): 226 - 231. [Abstract] [Full Text] [PDF]

				D. J. Kuo, N. J. Lacayo, S. Buck, R. Yu, C. Saraiya, L. Douglas, H. Weinstein, M. Chang, C. L. Willman, R. Tibshirani, et al. Gene Expression Profiling Identifies Genes Associated with In Vitro Resistance to Daunorubicin and Cytarabine in Children with De Novo Acute Myelogenous Leukemia (AML) from the Pediatric Oncology Group (POG) Study # 9421. Blood (ASH Annual Meeting Abstracts), November 16, 2004; 104(11): 1130 - 1130. [Abstract]